Brii highlights HBV functional cure potential at APASL 2025

31 March 2025

Brii Biosciences (HKEX: 2137) has reported promising interim results from its Phase II ENSURE study of elebsiran, a hepatitis B therapeutic, in combination with pegylated interferon, reinforcing its strategy to identify patients more likely to benefit from curative therapies.

The latest data, presented as a late-breaking oral session at the APASL 2025 meeting in Beijing, focused on a subset of patients who had previously responded to the company’s therapeutic vaccine, BRII-179 (recombinant protein-based hepatitis B immunotherapy).

At week 24, 56% achieved hepatitis B surface antigen seroclearance when treated with elebsiran plus pegylated interferon, compared to just 10% of non-responders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK